DFTX vs HELP: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DFTX and HELP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DFTX and HELP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Definium Therapeutics (Nasdaq: DFTX) is a clinical-stage biopharmaceutical company focused on brain-health and psychiatric disorders. It is the rebranded MindMed, having changed its name from Mind Medicine (MindMed) Inc. in January 2026. Its lead asset is DT120 ODT (formerly MM120), a proprietary orally disintegrating tablet formulation of lysergide (LSD) tartrate being developed for generalized anxiety disorder (GAD) and major depressive disorder (MDD), alongside DT402, an earlier-stage candidate in autism spectrum disorder (ASD). In June 2026 the company reported that its Phase 3 Emerge trial of DT120 in MDD met its primary and key secondary endpoints, and management has guided to multiple pivotal readouts across GAD and MDD during 2026.

Full DFTX guide

Cybin Inc., which began trading on the Nasdaq under the ticker HELP in early 2026 (previously CYBN on NYSE American) and adopted the operating name Helus Pharma, is a Toronto-based clinical-stage pharmaceutical company. Its lead program is HLP003 (also referenced as CYB003), a deuterated psilocybin analog being studied as an adjunctive treatment for major depressive disorder in a pivotal Phase 3 program called PARADIGM, which includes the APPROACH and EMBRACE studies. A second candidate, HLP004, a deuterated DMT compound, is in Phase 2 for generalized anxiety disorder. These are neuroactive serotonergic molecules designed to be administered in a supervised clinical setting.

Full HELP guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DFTX drivers: Late-stage psychiatry pipeline; Large unmet-need markets.
• HELP drivers: Phase 3 depression readout; Anxiety program optionality.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a pre-revenue clinical-stage company, Definium has no approved products and depends on trial outcomes, FDA decisions, and continued access to capital. For HELP, as a clinical-stage company, Cybin has negligible revenue and posts ongoing net losses, so it depends on trial success and repeated financing to survive.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DFTX if you believe its drivers more; HELP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DFTX and HELP guides.

DFTX. Traditional valuation multiples do not apply because Definium has essentially no revenue and reports net losses. The market capitalization of roughly $5.7 billion reflects expectations around DT120 rather than trailing financials, and the stock trades on clinical and regulatory milestones. The company has guided that its cash position funds operations into 2028.

HELP. Standard earnings multiples do not apply because Cybin has essentially no revenue and runs at a loss while funding Phase 3 trials. Much of its roughly $257 million market value is backed by its cash balance of around $195 million, so the market is assigning only a modest premium for the pipeline ahead of pivotal data. Valuation will hinge on trial outcomes and any resulting financing rather than on current financials.

Headline figures (approximate, JULY 2026): DFTX shows revenue (ttm) ~$0 (pre-revenue, no approved products), net loss (annual) ~$150M+ (clinical-stage cash burn), cash & investments ~$373M (Mar 2026) plus ~$700M raised, market cap ~$5.7B; HELP shows share price ~$5, market cap ~$257M, revenue (ttm) ~$0 (pre-revenue, under $1M), cash ~$195M (end of 2025).

DFTX and HELP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DFTX and HELP exposure against your real portfolio. It is not an investment adviser.